+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients



Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients



American Journal of Medicine 104(1): 33-39



Oropharyngeal candidasis (thrush) is the most common opportunistic infection in individuals who are positive for the human immunodeficiency virus (HIV) and those who have progressed to AIDS. Itraconazole has a broad in vitro spectrum of activity, including a wide variety of Candida species. Our study determined the relative efficacy of a new oral solution formulation of itraconazole and fluconazole tablets in the treatment of oropharyngeal candidiasis. This was a prospective randomized, third-party-blind, multicenter trial conducted at 12 centers in the United States. One hundred seventy-nine HIV-positive patients with mycologically documented oropharyngeal candidiasis were treated with itraconazole oral solution 200 mg/ day for 7 or 14 days, or fluconazole tablets 100 mg/day for 14 days. Severity of disease was scored clinically before treatment and at clinical evaluations on days 3, 7, 14, 21, 35, and 42. Semi-quantitative cultures of mouth washings were also obtained on these days. Both 14-day and 7-day regimens of itraconazole oral solution were equivalent to fluconazole for most efficacy parameters. The clinical response rate was 97% after 14 days of itraconazole and 87% after 14 days of fluconazole. Itraconazole oral solution given for 7 days was also equivalent to fluconazole treatment for 14 days. Approximately one half of patients in all three groups relapsed by 1 month after completion of treatment. There were few adverse reactions to either drug. Itraconazole oral solution is well tolerated and offers an alternative at least as effective as fluconazole in the treatment of oropharyngeal candidiasis.

(PDF emailed within 0-6 h: $19.90)

Accession: 047169143

Download citation: RISBibTeXText

PMID: 9528717

DOI: 10.1016/s0002-9343(97)00307-0


Related references

Evaluation of efficacy and safety of itraconazole oral solution for the treatment of oropharyngeal candidiasis in aids patients. Brazilian Journal of Infectious Diseases 5(2): 60-66, 2001

A Double-Blind Comparison of Itraconazole Oral Solution and Fluconazole Capsules for the Treatment of Oropharyngeal Candidiasis in Patients with Aids. Clinical Infectious Diseases 26(6): 1368-1373, 1998

A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. Clinical Infectious Diseases 26(6): 1368-1373, 1998

Itraconazole oral solution for the treatment of oropharyngeal candidiasis Results of two randomized, blinded studies. ELEVENTH INTERNATIONAL CONFERENCE ON AIDS Eleventh International Conference on AIDS, Vol One One world: One hope : 17, 1996

Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients. Aids Research and Human Retroviruses 15(16): 1413-1417, 1999

Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients. Clinical Therapeutics 19(3): 471-480, 1997

Fluconazole versus itraconazole in therapy of oropharyngeal candidiasis in cancer patients: a prospective comparative randomized trial. Journal of ChemoTherapy 7 Suppl 4: 204-205, 1995

Randomized study of fluconazole oral solution versus amphotericin B oral solution in oropharyngeal candidiasis in elderly patients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 38: 490, 1998

Randomized study of floconazole oral solution versus amphotericin oral solution in oropharyngeal candidiasis in head and neck cancer patients after radiotherapy. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 38: 488, 1998

Itraconazole oral solution versus fluconazole treatment of oropharyngeal candidiasis. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 35(0): 244, 1995

Itraconazole solution for fluconazole-refractory oropharyngeal candidiasis in AIDS Correlation of clinical response with in vitro susceptibility. TENTH INTERNATIONAL CONFERENCE ON AIDS, INTERNATIONAL CONFERENCE ON STD Tenth International Conference on AIDS and the International Conference on STD, Vol 2; The global challenge of AIDS: Together for the future : 2) 23, 1994

Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility. Aids 10(12): 1369-1376, 1996

Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Clinical Infectious Diseases 24(6): 1204-1207, 1997

An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. Journal of Antimicrobial ChemoTherapy 57(2): 317-325, 2005

Clinical trial: clotrimazole troche vs. itraconazole oral solution in the treatment of oral candidosis in AIDS patients. International Journal of Dermatology 39(11): 859-861, 2000